Compare LMT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMT | SNY |
|---|---|---|
| Founded | 1912 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.8B | 104.5B |
| IPO Year | 1995 | N/A |
| Metric | LMT | SNY |
|---|---|---|
| Price | $540.33 | $44.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $602.71 | $58.00 |
| AVG Volume (30 Days) | 993.0K | ★ 2.3M |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | 2.71% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.44 | N/A |
| Revenue | ★ $75,048,000,000.00 | N/A |
| Revenue This Year | $6.55 | $3.49 |
| Revenue Next Year | $5.07 | $6.10 |
| P/E Ratio | $85.25 | ★ $6.14 |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $410.11 | $42.28 |
| 52 Week High | $692.00 | $52.68 |
| Indicator | LMT | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.41 | 50.79 |
| Support Level | $505.21 | $43.32 |
| Resistance Level | $541.21 | $45.18 |
| Average True Range (ATR) | 10.74 | 0.57 |
| MACD | 4.00 | 0.14 |
| Stochastic Oscillator | 72.08 | 68.58 |
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.